NOVARTIS AG NVS

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $150.91
Market Cap $289.38B
P/E Ratio 21.11
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑9.6% YoY
$56.67B
3-Yr CAGR: 3.0%
Net Income ↓-750.0% YoY
-$17.00M
Net Margin: -0.0%
Free Cash Flow ↓-41.2% YoY
-$1.24B
FCF Yield: -0.43%
EPS (Diluted) ↑21.8% YoY
$7.15
Basic: $7.21
Return on Equity Efficiency
N/A
ROA: -0.0%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVS)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $49,436.0M $31,916.0M $-14.0M $43.0M $-1,819.0M
FY 2017 $50,135.0M +1.4% $32,960.0M +100.0% $3.17 $97.0M $-1,599.0M +12.1%
FY 2018 $53,166.0M +6.0% $34,759.0M $3.0M $5.46 +72.2% $243.0M $-1,530.0M +4.3%
FY 2019 $48,677.0M -8.4% $34,252.0M $5.0M +66.7% $3.08 -43.6% $214.0M $-1,165.0M +23.9%
FY 2020 $49,898.0M +2.5% $34,777.0M $-1.0M -120.0% $3.52 +14.3% $47.0M $-1,228.0M -5.4%
FY 2021 $52,877.0M +6.0% $37,010.0M $-3.0M -200.0% $10.63 +202.0% $13.0M $-1,365.0M -11.2%
FY 2022 $51,828.0M -2.0% $36,342.0M +100.0% $2.76 -74.0% $254.0M $-944.0M +30.8%
FY 2023 $46,660.0M -10.0% $34,188.0M $4.0M $4.10 +48.6% $645.0M $-415.0M +56.0%
FY 2024 $51,722.0M +10.8% $38,895.0M $-2.0M -150.0% $5.87 +43.2% $489.0M $-877.0M -111.3%
FY 2025 $56,674.0M +9.6% $42,975.0M $-17.0M -750.0% $7.15 +21.8% $310.0M $-1,238.0M -41.2%
$

Valuation

Market Price $150.91
Market Cap $289.38B
Enterprise Value N/A
P/E Ratio 21.11
P/B Ratio N/A
FCF Yield -0.43%
Dividend Yield N/A
Shares Outstanding 1,908,092,000
%

Profitability & Margins

Gross Margin 75.83%
Operating Margin 31.13%
Net Margin -0.03%
Return on Equity (ROE) N/A
Return on Assets (ROA) -0.02%
Asset Turnover 0.51x
Revenue 3-Yr CAGR 3.02%
🛡️

Financial Health & Liquidity

Current Ratio 0.10
Cash Ratio N/A
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share N/A
💧

Cash Flow Efficiency

Operating Cash Flow $310.00M
Capital Expenditures (CapEx) $1.55B
Free Cash Flow -$1.24B
OCF / Revenue 0.55%
FCF / Revenue -2.18%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $7.15
EPS (Basic) $7.21
Dividends / Share N/A
Book Value / Share N/A
EPS YoY Growth 21.81%
🏛️

Balance Sheet (FY 2025)

Total Assets $110.95B
Total Liabilities $64.40B
Stockholders' Equity N/A
Current Assets $205.00M
Current Liabilities $1.97B